The recent surge in capital into niche pharmaceutical companies, particularly those focusing on groundbreaking therapies and challenging drug development programs, has fueled what some are calling "High Roller Pharma." While the promise for blockbuster treatments and substantial returns is certain, the linked risks are also notable. Many of thes… Read More